Copenhagen 4-6 May 2015 at the Radisson Blu Scandinavia
The purpose of the CMC Strategy Forum is to provide a venue for biotechnology/biological product discussion. The Forums focus on relevant CMC issues throughout the lifecycle of a product and thereby foster collaborative technical and regulatory interactions. The Forum strives to share information with the regulatory agencies to assist them in merging good scientific and regulatory practices.
Following on the growing interest in the CMC Strategy Forum globally, a CMC Strategy Forum Europe series was launched in 2007 in Brussels, Belgium and has rapidly become a very successful annual event that draws regulators and industry professionals across Europe. The CMC Strategy Forum Europe is aimed at fostering global interactions and harmonization. With the strong support from the Pharmaceuticals and Medical Devices Agency (PMDA), we organized the CMC Strategy Forum Japan in 2012, 2013 and 2014 with great feedback and broad engagement. More recently, CASSS organized the inaugural CMC Strategy Forum Latin America in 2014 with strong support from the National Health Surveillance Agency (ANVISA), as well as GrupoFarmaBrasil, Interfarma-Association of Pharmaceutical Research and several other Latin America regulatory agencies (Chile, Cuba and Peru). The success of the Forum series in the United States, Europe, Japan and now Latin America, further demonstrates the benefits and need for providing an open forum for dialogue and exchange of scientific and technical advances that are the basis for evolution of regulatory practices.
Is there a possibility for us to partner with your association so that we can get the message to the local biopharmaceutical industry that the CMC Strategy Forum Europe is being held in their backyard this year? Please let me know what kind of information you need from me to move forward. In the meantime, please take a look at our website – http://www.casss.org/- as well as the CMC Strategy Forum Europe 2015 website – http://www.casss.org/?CMCE1500 – so that you have more of an idea as to who we are and what we offer to the biopharmaceutical industry. I look forward to hearing from you shortly.